<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594671</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ATR-2010-23</org_study_id>
    <nct_id>NCT01594671</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Unilateral Total Knee Arthroplasty</brief_title>
  <acronym>TRANEXTOP</acronym>
  <official_title>Prevention of Postoperative Blood Loss: Randomised Multicentre Parallel Clinical Trial That Assess the Topical and Intravenous Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee arthroplasty is often associated with excessive postoperative bleeding due to
      increased fibrinolysis. Hence, the objective of the proposed of this multicentre study is to
      determine the peri-operative bleeding comparing the application of topical and intravenous
      tranexamic acid with the habitual surgical haemostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        1. Principal: To assess if the topical and intravenous tranexamic acid reduce less or at
           least than 20% the blood losses with respect to the habitual haemostasia in patients,
           after unilateral total knee arthroplasty.

        2. Secondary: To assess the treatment safety. To perform a cost- analyses.

      Methods: Randomized, multicentre, open and parallel clinical trial with three comparative
      groups: Topical tranexamic acid, Intravenous tranexamic acid and habitual haemostasia. In all
      patients, a single drainage of 8mm will be inserted in the joint, and it will remain closed
      during one hour after the closure of the skin.

      Nº of participant centres: 2. Random allocation will be centralised in &quot;Hospital de la Santa
      Creu i Sant Pau&quot;.

      Main outcome: Total blood loss (mL) in the post-operative period collected by the habitual
      drain system ).

      Secondary outcomes: Total blood loss (mL)and hidden blood calculated by Nadler's formula.
      Proportion of patients with blood transfusion, complications of surgery wound, haemoglobin
      pre and post-operative, units of blood transfused, post-operative mortality, days of hospital
      stay, safety of interventions assessed.Direct cost analysis.

      Substudy: Pharmacokinetic study. The first 24 patients included in &quot;Hospital de la Santa Creu
      i Sant Pau&quot; for tranexamic acid (12 topical- 12 intravenous) to determine:

        1. Plasmatic concentrations of tranexamic acid

        2. In topical and intravenous tranexamic acid administration determine the absorption rate
           and drug bioavailability by these routes: maximum plasma concentration, time to reach
           Cmax, AUC, and half-life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss (mL)</measure>
    <time_frame>at 24 hours postoperatively</time_frame>
    <description>Blood will be collected by drainages during the first 24 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hidden blood loss</measure>
    <time_frame>From admission to hospital until an average of 5 days postoperative period</time_frame>
    <description>Hidden blood loss will be calculated by Nadler's formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>5 weeks postoperatively</time_frame>
    <description>We will quantify infections, haematomas and other complications related with surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect related with the interventions</measure>
    <time_frame>5 weeks postoperatively</time_frame>
    <description>Any adverse effects related with tranexamic acid will be collected</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual haemostasia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The surgical habitual haemostasia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Amchafibrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.</description>
    <arm_group_label>Topical Tranexamic acid</arm_group_label>
    <other_name>Amchafibrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>haemostasia</intervention_name>
    <description>The surgical habitual haemostasia: electrocoagulation of the bleeding tissues</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_label>Habitual haemostasia</arm_group_label>
    <arm_group_label>Topical Tranexamic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral Total knee arthroplasty

          -  The patient consent to participate

        Exclusion Criteria:

          -  Antecedent of thromboembolic disease

          -  Patient with cardiac alterations of the rhythm

          -  Patients with valvular cardiac prosthesis

          -  Patients with pro-thrombotic alterations of coagulation

          -  Treatment with anticonceptive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aguilera X, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martinez-Zapata MJ, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Cochrane Iberoamericano. IIB Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Esperanza</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>December 18, 2012</last_update_submitted>
  <last_update_submitted_qc>December 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary knee arthroplasty</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

